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Abstract: Direct intercellular communication, mediated by gap junctions formed by the connexin
transmembrane protein family, is frequently dysregulated in cancer. Connexins have been described
as tumour suppressors, but emerging evidence suggests that they can also act as tumour promoters.
This feature is connexin- and tissue-specific and may be mediated by complex signalling pathways
through gap junctions or hemichannels or by completely junction-independent events. Lung cancer
is the number one cancer in terms of mortality worldwide, and novel biomarkers and therapeutic
targets are urgently needed. Our objective was to gain a better understanding of connexins in this
setting. We used several in silico tools to analyse TCGA data in order to compare connexin mRNA
expression between healthy lung tissue and lung tumours and correlated these results with gene
methylation patterns. Using Kaplan-Meier plotter tools, we analysed a microarray dataset and an
RNA-seq dataset of non-small cell lung tumours in order to correlate connexin expression with
patient prognosis. We found that connexin mRNA expression is frequently either upregulated or
downregulated in lung tumours. This correlated with both good and poor prognosis (overall survival)
in a clear connexin isoform-dependent manner. These associations were strongly influenced by the
histological subtype (adenocarcinoma versus squamous cell carcinoma). We present an overview
of all connexins but particularly focus on four isoforms implicated in lung cancer: Cx26, Cx30.3,
Cx32 and Cx43. We further analysed the protein expression and localization of Cx43 in a series of
73 human lung tumours. We identified a subset of tumours that exhibited a unique strong nuclear
Cx43 expression pattern that predicted worse overall survival (p = 0.014). Upon sub-stratification, the
prognostic value remained highly significant in the adenocarcinoma subtype (p = 0.002) but not in
the squamous carcinoma subtype (p = 0.578). This finding highlights the importance of analysis of
connexin expression at the protein level, particularly the subcellular localization. Elucidation of the
underlying pathways regulating Cx43 localization may provide for novel therapeutic opportunities.
Keywords: connexins; Cx43; gap junctions; lung cancer; immunohistochemistry; prognosis; nuclear
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1. Introduction
The World Health Organization (WHO) currently estimates that 1.69 million deaths per year
worldwide are due to lung cancer, far more than any other cancer type. Non-small cell lung cancer
(NSCLC), which includes the two major subtypes of lung adenocarcinoma (LUAD) and lung squamous
cell carcinoma (LUSC), accounts for about 85% of lung cancers. In terms of the biology of lung cancer,
significant advances have been made [1]. Indeed, LUAD and LUSC has been shown to originate from
different cells and have unique molecular characteristics leading to distinct biological and pathological
patterns needing different therapeutic strategies. The delineation of specific oncogenic pathways has
allowed stratification of tumours and incorporation of patient-specific targeted therapy based on, for
example, the activation status of receptor tyrosine kinases such as epidermal growth factor receptor
(EGFR) [1]. Nevertheless, lung cancer is a highly heterogeneous disease at both the histological and
molecular levels, and metastasis is frequently present at diagnosis, which together result in a poor
overall survival (OS) rate [1]. Thus, identification of additional biomarkers, elucidation of the full
oncogenic circuit defining these tumours and novel treatment approaches are some of the steps needed
for the future management of this disease.
Lung tissue homeostasis is thought to be tightly controlled through multiple mechanisms,
including direct gap junction-mediated intercellular communication (GJIC). Gap junctions are formed
by transmembrane proteins named connexins that assemble into hexameric structures called connexons,
which act as hemichannels that can dock with hemichannels in adjacent cells forming an intercellular
channel. The 21-member family of human connexin proteins ranges in size between 23 and 62 kDa
(Cx23-Cx62) [2]. It is also thought that hemichannels may additionally communicate with the
extracellular matrix under specific pathological conditions such as cancer [3]. Moreover, several
connexins (most notably Cx43) have been shown to possess functions unrelated to the formation
of junctional complexes [4,5]. GJA1, which encodes Cx43, has been shown to synthesize several
truncated protein forms through a process of internal translation initiation regulated by key cancer
signalling pathways such as mTOR and Mnk1/2 [6–8]. The role of these protein forms is currently
being explored but includes an interaction with the cytoskeleton and mitochondria [9–11] and the
regulation of epithelial to mesenchymal transition (EMT) [12,13].
A variety of connexins are expressed in lung tissue and are thought to be critical for lung
physiology, function and host defences under normal and pathological conditions [14]. Cx26 and Cx43
have been detected in human epithelial cells of the respiratory airways, whereas a variety of additional
connexins has been detected in murine models, including Cx32, Cx37 and Cx46 [14]. Targeting of
connexins has been proposed as a viable approach in terms of the management of lung diseases such
as cancer [15]. The importance of connexins in cancer in general has been widely studied in vitro and
in vivo for more than 50 years, with the work revealing extensive tissue- and connexin-dependent
variations [16].
Several studies have shown that connexins may play an important role in lung cancer.
Some in vitro studies have suggested a tumour suppressor role for connexins in the lung. Notably,
Cx43 gene transfection can inhibit the migration of the human lung squamous carcinoma cell line
NCI-H226 [17]. Other work showed that Cx43 may recruit E-cadherin to inhibit the malignant behaviour
of lung cancer cells [18]. Cx43 also suppresses lung cancer cell invasion and metastasis, possibly by
acting as a “histone deacetylase inhibitor” affecting the gene expression of several genes, such as by
increasing the expression and secretion of FSTL1 (follistatin-like 1) [19]. A recent study demonstrated
that overexpression of Cx43 in lung cancer cell lines represses cancer stem cells and associated malignant
features [20]. Downregulation of Cx26 expression has been shown to occur in several human lung
cancer cell lines due to gene promoter methylation [21]. Cx31.1 is also downregulated in NSCLC cell
lines, and Cx31.1 re-expression inhibits cell proliferation and metastasis [22]. Degradation of Cx31.1 in
lung cancer may also involve clathrin-mediated autophagy [23].
Connexins can also influence the effect of chemotherapy. In A549 LUAD cells, Cx32 increases
vinorelbine-induced cytotoxicity by reducing the expression of the multidrug resistance-1 (MDR-1)
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gene [24]. Other major pathways regulated by Cx32 in lung cancer cells include inhibition of Src
activity [25].
Murine models support the link between connexins and lung cancer [16]. Notably, Cx32 knockout
mice exhibit a significantly increased incidence of chemical and radiation-induced lung tumours [26,27],
likely in part due to activation of the MAPK pathway. Surprisingly, these mice do not show obvious
pulmonary alterations but are susceptible to benzene-induced lung toxicity [28]. Cx32-deficient
mice seem to display increased proliferation of non-tumoral alveolar epithelial type II (ATII), from
which lung tumours originate [26–28]. Cx43 heterozygote knockout mice also display increased
cell proliferation of ATII cells [29]. A higher incidence of LUADs induced by DMBA is seen in this
model [30]. Paradoxically, however, despite higher susceptibility of spontaneous and NNK-induced
lung neoplasms, Cx43 mRNA is significantly increased during tumour progression and correlates with
increased tumour aggressiveness [31].
In addition, a number of reports have shown altered connexin expression in human tumours.
Various studies have suggested promotor methylation regulate connexin expression in cancer [32,33].
Decreased expression of Cx43 at the mRNA and protein levels due to promoter methylation has
been shown to occur during NSCLC tumour progression [34]. Hypermethylation of the GJA1 (Cx43)
promoter has been significantly associated with heavy smoking, poorly differentiated NSCLC and low
expression of Cx43 [35]. There is also strong evidence that promoter methylation can cause decreased
Cx26 expression in lung tumours [21]. Cx32 has been positively correlated with the degree of tumour
differentiation and survival rates of NSCLC patients [36]. However, Cx26 was not correlated with
smoking, tumour size, histological type, the degree of differentiation, lymph node metastasis and the
postoperative survival time [36]. More recently, expression of Cx43 at the time of diagnosis was shown
to predict survival in advanced NSCLC patients treated with cisplatin-based chemotherapy [37].
However, although connexins have typically been classified as tumour suppressors, accumulating
data suggest that connexins can also promote tumour progression in certain tissues and at certain
cancer stages [16,38,39]. This dichotomy is also observed in lung cancer, both in vitro and in vivo,
which again depends on the connexin isoform. For example, Cx43 reverses cisplatin resistance in
A549 LUAD cells by inhibiting EMT [40]. In contrast, Cx26 (in a GJIC-independent manner) induces
EMT via the PI3K-AKT signalling pathway and confers resistance to the EGFR inhibitor gefitinib in
HCC827 and PC9 LUAD cells [41]. Indeed, increased expression of Cx26 at the invasive front of LUSC
was shown to be significantly correlated with poor prognosis [42]. Other studies have implicated
Cx43 in this process through enhanced attachment of lung tumour cells to the endothelium that
facilitates extravasation, a critical feature for efficient metastasis [43]. Recently, a clear pro-tumorigenic
role for Cx43 in lung cancer and metastasis to the brain was demonstrated. In a series of elegant
experiments, Massagué and colleagues [44] showed that lung (and breast) carcinoma cells upregulate
Cx43 expression and establish heterocellular GJIC with astrocytes in the brain, creating a cell signalling
feedback loop that fosters tumour growth and chemoresistance. FDA-approved compounds that
block GJIC significantly inhibit metastasis growth. Others have shown that GJIC-mediated transfer of
small RNAs from lung cancer cells to astrocytes can alter cancer cell resistance to chemotherapy [45].
More recently, Cx30.3 was shown to be overexpressed in lung tumours and to be associated with poor
prognosis and recurrence [46]. Functionally, Cx30.3 appears to activate the c-Src proto-oncogene to
induce a number of cellular traits associated with malignancy.
Thus, there are highly conflicting reports with regards to the pro-tumorigenic and anti-tumorigenic
functions of connexins in lung cancer. In addition to GJIC-mediated mechanisms, non-junctional
connexin functions must also be carefully considered in lung cancer. Notably, the role of nuclear
Cx43 remains to be explored. Nuclear Cx43 has been described in some human tumours including
glioma [47] and colon tumours [48]. Nuclear Cx43 was described in lung cancer cell lines more than
20 years ago [49]. Indeed, overexpression of oncogenes such as c-Src and Her2 (frequently observed
in the lung) was shown to correlate with nuclear Cx43 localization in rat liver epithelial cells [50].
More recently, Cx43 was shown to be translocated to the nucleus in late G1 of the cell cycle via binding
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to A-kinase anchoring protein 95 in lung A549 adenocarcinoma cells [51]. Nuclear localization of a
truncated form of Cx43 has also been described in a glioma cell line [52]. This is of interest in relation
to the recent discovery of the active translation of truncated Cx43 isoforms (notably the GJA1-20k
form) [6–8,33], which we showed also occur in human lung tumour cell lines under regulation of
oncogenic pathways frequently activated in lung cancer such as mTOR and MAPK-Mnk1/2 kinases [7].
Very recently, the major truncated form of Cx43 (GJA1-20k) was shown to regulate EMT by acting as a
direct nuclear transcriptional activator of N-cadherin [13].
To answer some of the discrepancies and outstanding questions discussed above, we have
analysed the gene expression profile of the entire connexin family in order to identify the overall
correlation tendency between connexin mRNA expression and tumour prognosis. In addition,
we analysed the protein expression of Cx43, with particular emphasis on potential non-junctional
functions due to, for example, nuclear localization. Our results highlight the fact that connexins show
both pro- and anti-tumour propensities in lung cancer. This depends significantly on the connexin
isoform and the lung cancer subtype. Moreover, protein expression and connexin localization are
important from a biomarker perspective. Indeed, we show that Cx43 is localized to the nucleus in
a subset of lung tumours, particularly in adenocarcinomas, and that this is associated with poor
prognosis. Elucidation of the complex role of connexins in lung cancer is critical for the development
of therapeutic approaches.
2. Results
2.1. Connexin mRNA Expression in Human Lung Tumours and Normal Healthy Tissue
We compared the mRNA expression levels of different connexins between healthy lung tissue
and lung tumours with the online in silico analysis tool FireBrowseR (http://firebrowse.org/) using
publically available The Cancer Genome Atlas (TCGA) data [53]. We observed significant changes in
mRNA gene expression in a number of connexins (Table 1, and associated graphics in Supplementary
Figure S1 that include expression variability and the presence of outliers). Our overall conclusions
from these observations were verified using the TCGA Wanderer tool (http://maplab.imppc.org/
wanderer/) based on Illumina HiSeq RNA-seq analysis [54].
Table 1. Summary of fold-changes in connexin mRNA expression in lung adenocarcinoma (LUAD)
and lung squamous cell carcinoma (LUSC) compared with normal healthy tissue.
Regulation Cx Gene LUAD LUSC
Up
Cx46 GJA3 1.74 35.6
Cx59 GJA9 3.01 1.82
Cx26 GJB2 14.4 63.5
Cx31 GJB3 3.27 34.4
Cx30.3 GJB4 1.88 29.4
Cx31.1 GJB5 1.66 59.9
Cx30 GJB6 7.47 289
Down
Cx37 GJA4 0.36 0.18
Cx40 GJA5 0.32 0.17
Cx50 GJA8 0.83 0.97
Cx45 GJC1 0.67 0.76
Cx47 GJC2 0.325 0.234
Cx30.2 GJC3 0.817 0.61
Cx31.9 GJD3 0.52 0.43
Cx40.1 GJD4 0.89 0.96
Mixed
Cx43 GJA1 0.31 1.33
Cx32 GJB1 1.49 0.064
Cx25 GJB7 0.41 7.18
Cx36 GJD2 0.56 2.9
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Compared with healthy tissue, a significant number of connexin genes were highly upregulated
in the tumours, particularly in the LUSC subtype. A number of connexins displayed moderate
downregulation, whereas other isoforms showed a mixed response dependent on the tumour subtype
analysed. We focused on four connexin genes—Cx26, Cx30.3, Cx32 and Cx43—thought to play a
role in lung cancer based on previous research (including mouse models). This group of four genes
behaved very differently and clearly illustrated the varied changes in gene expression that can occur
in connexin genes in lung cancer (Figure 1). Notably, compared with healthy tissue, there was a
significant 14.4-fold and 63.5-fold upregulation of Cx26 mRNA expression in LUAD and LUSC,
respectively (Figure 1a). GJB4 encoding Cx30.3 also displayed a significant 29.4-fold upregulation in
LUSC (Figure 1b). This seemed to occur in several other beta-connexins (e.g., GJB6 encoding Cx30; see
Table 1) that are typically expressed in differentiated squamous epithelial cells (e.g., skin keratinocytes).
Cx26 and Cx30.3 have been suggested to be pro-tumorigenic in the lung, and the in silico data
supported this notion based on the idea that overexpression may drive tumour progression. However,
for GJB1 encoding Cx32, whose knockout mice are more susceptible to lung tumour formation, only a
slight upregulation (1.45-fold) was seen in LUAD, whereas it was significantly downregulated in LUSC
(0.064-fold) (Figure 1c). This further points to important connexin isoform and cancer subtype-specific
differences. The role of GJA1 encoding Cx43 is controversial in lung cancer and, although this gene is
highly expressed, there are only modest changes to its gene expression in the tumours (Figure 1d), with
a slight downregulation in LUAD (0.31-fold) and slight upregulation in LUSC (1.33-fold). The overall
changes in gene expression in all connexins is clearly diverse (Table 1), and it is likely that complex
mechanisms, including epigenetic regulation, control the abundance of connexin mRNAs.
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Figure 1. Connexin mRNA gene expression in normal tissue (blue) and in LUAD and LUSC tumours
(red). (a) Expression of GJB2 (encoding Cx26). Significant upregulation is seen in both tumour
subtypes, particularly LUSC. (b) Expression of GJB4 (encoding Cx30.3) is mainly upregulated in LUSC.
(c) Expression of GJB2 (encoding Cx32) is specifically downregulated in LUSC. (d) Expression of GJA1
(encoding Cx43) is high in normal tissue but shows only a slight upregulation in LUAD and a slight
downregulation in LUSC. The figure also highlights the occurrence of some outliers in tumours, such
as very low expression of Cx26 and Cx30.3 in some LUSCs despite a general upregulation and very
high expression of Cx32 in some LUSCs despite a general downregulation.
2.2. Regulation of Connexins at the DNA and mRNA Levels in Relation to Lung Cancer
We performed further in silico-based analysis of the four key lung cancer-associated connexins
that we described in Section 2.1 and that showed significant changes in gene expression in healthy
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versus tumour tissues. One of the key regulators of gene transcription is gene methylation. We used
an online (http://ualcan.path.uab.edu/) analysis tool [55] to gain insight into the correlation between
the changes in connexin mRNA expression in lung tumours and changes in gene methylation. As seen
in Figure 2, methylation-specific changes were connexin and tumour subtype-specific.
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Figure 2. Methylation statuses of Cx26 (GJB2), Cx32 (GJB1), Cx30.3 (GJB4) and Cx43 (GJA1) in LUSC
and LUAD compared with normal healthy lung tissue. The Beta value indicates the level of DNA
methylation and ranges from 0 (unmethylated) to 1 (fully methylated). Different beta value cutoff values
have been considered [56,57] to indicate hyper-methylation [Beta value: 0.5–0.7] or hypo-methylation
[Beta value: 0.25–0.3].
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Moreover, no strict correlation could be inferred between methylation status and the observed
gene expression or changes in gene expression (Figure 1). For example, GJB2 (encoding Cx26) was
dramatically upregulated in LUAD and especially in LUSC (Figure 1a). This partially correlated
with a slight demethylation in LUSC (suggesting increased transcription). However, increased
methylation (silencing) is seen in LUAD. Overall, however, GJB2 seemed to be hypomethylated
(a state considered [56,57] to occur with a Beta value in the range around or below 0.25–0.30), which
favours trancription. GJB1 (Cx32) appeared to be generally hypermethylated (a state considered [56,57]
to occur with a Beta value in the range around or above 0.5–0.7). Some demethylation seemed to
occur in LUSC (Figure 2b), but this actually contrasted with the loss of gene expression observed in
this tumour subtype (Figure 1c). Better correlation was seen for GJB4 (Cx30.3; Figure 2c) where some
demethylation occurred (although the gene is still considered highly methylated), which corresponds
to increased mRNA levels (Figure 1) in both tumour subtypes. GJA1 (Cx43) is thought to be the most
highly expressed connexin in lung tissue and tumours (Figure 1) yet it is highly methylated (Figure 2d).
We also used the TCGA Wanderer tool (http://maplab.imppc.org/wanderer/) [54] to analyse the
methylation status of select connexins using individual probes. We confirmed our previous observation
that the gene methylation status did not correlate well with the dramatic changes observed in gene
expression (Supplementary Figure S2). For example, significant loss of Cx32 gene expression was
observed in LUSC (see Table 1 and Figure 1c). However, all methylation probes—many of them with
statistical significance, including those at the CpG island (green)—showed an overall reduced degree
of methylation (more so in LUSC than in LUAD) (Supplementary Figure S2). This typically indicated
increased rather than decreased transcription. Another example is Cx30, which showed a massive
289-fold upregulation in LUSC yet only minor changes in methylation status, and the most notable
changes occured in LUAD rather than LUSC (Supplementary Figure S2). Other genes showed a better
correlation. Notably, demethylation of GJB5 (particularly in LUSC) correlated with the observation that
the mRNA expression of this gene was significantly upregulated in tumours (Supplementary Figure S2).
Small individual regions can be sufficient to significantly influence transcription. Indeed, although
there were no major overall changes in the methylation status of GJB2 (encoding Cx26; Figure 2a),
a noticeable demethylation was seen in probe cg24425972 in LUSC (Figure 2a,b) compared with
normal tissues, which correlates well with the observed significant upregulation of the mRNA
expression-based Illumina HiSeq RNA-seq (Figure 2b, see also Figure 1a). A similar pattern was
seen in LUAD where there was slightly less demethylation, which corresponds to the less significant
upregulation of mRNA in this tumour type (Supplementary Figure S2).
We also screened whether any connexin gene has been identified to show any correlation between
methylation and clinical features using FirebrowseR (http://firebrowse.org/) [53]. Indeed, among
only 30 genes identified, methylation of GJB2 (encoding Cx26) was associated with tumour stage
in LUAD (Kruskal-Wallis p-value = 0.0001923, Q value = 0.119). Thus, although there was a poor
direct correlation between mRNA expression and methylation status in many connexin genes, specific
correlations could be identified and may be biologically and clinically significant.
2.3. Connexin mRNA Expression Is Associated with Both Poor and Good Prognosis, Which Depends on Both
Lung Cancer Subtype and Connexin Isoform
We used a dedicated lung cancer-specific Kaplan-Meier survival analysis tool [58] to correlate
connexin mRNA expression (from arrays, n = 2435) with the OS of patients. We analysed all gap
junction genes with valid probes available (n = 18). The overall results for lung cancer as a whole
are summarised in Table 2. A substantial amount of insightful information can be drawn from this
summary. First, there are major differences between different connexin isoforms. Some connexins are
associated with better prognosis, whereas others are associated with poor prognosis. Critically, this
seems highly dependent on the tumour subtype.
We paid particular attention to connexin genes known to play a role in lung cancer, namely,
Cx26, Cx30.3, Cx32 and Cx43. Of these, only Cx43 was associated with better prognosis in both the
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LUSC and LUAD subtypes (Figure 3a). However, the relatively small change in the hazard ratio
(HR, chance of death) suggests that this association has quite a low impact (although it is highly
significant statistically).
Table 2. Summary of the overall survival (OS) of patient cohorts grouped into cohorts expressing
either high or low levels of connexin mRNA in non-small cell lung cancer (NSCLC) in general, lung
adenocarcinoma (LUAD) or lung squamous cell carcinoma (LUSC) compared with normal healthy tissue.
Gene Connexin HRNSCLC
OS Change
(Months)
High Cx
HR LUSC
OS Change
(Months)
High Cx
HR LUAD
OS Change
(Months)
High Cx
GJA1 Cx43 0.84 * +19 0.78 +24 0.64 * +49
GJA3 Cx46 1.42 * −41 0.77 +27 1.48 * −42
GJA4 Cx37 0.67 * +43 0.83 +22 0.67 * +45
GJA5 Cx40 1.30 * −23 1.20 −4 1.86 * −69
GJA8 Cx50 1.18 −11 1.16 −17 0.60 * +59
GJA10 Cx62 1.20 −28 0.77 +24 1.62 * −52
GJB1 Cx32 0.71 * +31 1.38 −24 0.60 * +59
GJB3 Cx31 1.56 * −37 1.27 −21 2.39 * −114
GJB4 Cx30.3 1.31 * −23 1.18 −15 1.88 * −62
GJB5 Cx31.1 1.52 * −36 1.12 −12 1.63 * −57
GJB6 Cx30 1.40 * −38 0.75 +29 0.82 +11
GJB2 Cx26 1.49 * −47 0.87 +16 2.12 * −56
GJC1 Cx45 0.73 * +36 1.22 −15 0.66 * +37
GJC2 Cx47 1.13 −6 0.81 +27 1.45 * −41
GJC3 Cx30.2 1.26 * −27 0.78 +8 1.76 * −53
GJD2 Cx36 1.25 * −18 1.14 −11 2.13 * −68
GJD3 Cx31.9 0.68 * +39 0.66 * +24 1.26 −44
GJD4 Cx40.1 1.25 * −22 0.83 +27 1.49 * −33
1.Abbreviations: HR, hazard ratio; OS, overall survival; NSCLC, non-small cell lung cancer; LUSC, squamous cell
lung cancer; LUAD, adenocarcinoma lung cancer; Cx, connexin. 2. The table depicts the patient hazard ratio, where
the cohort expressing high levels of connexin mRNA is either associated with better survival (depicted in green,
HR less than 1, i.e., less chance of death, suggesting the connexin is a tumour suppressor) or with worse survival
(red, HR greater than 1, i.e., higher chance of death, suggesting the connexin is pro-tumorigenic). The average
change in survival (months) is the difference between the patient cohorts grouped as having high and low levels
of connexins. Those associations with a significant statistical difference (p < 0.01) are in bold and marked with an
asterisk *. Further detail and individual Kaplan-Meier curves can be seen in Supplementary Figure S3.
This correlates with the rather minimal change in gene expression between healthy and tumour
tissue (Figure 1d). On the other hand, high Cx32 expression predicted better survival in overal NSCLC
and LUAD patients, whereas LUSC patients had a tendency to perform worse if grouped in the
cohort with high Cx32 expression (Figure 3b). The recent findings that Cx30.3 is linked to tumour
progression [46] are strongly supported by our in silico analysis, which predicted significantly worse
survival in the NSCLC group and the LUAD subtype (Figure 3c). Notably, other connexins (such as
Cx31, known to be expressed in lung cancer) seemed to follow a similar pattern (Table 2). Cx26 predicts
a poor outcome for NSCLC in general, and a significantly worse prognosis in the LUAD subgroup
(HR = 2.12), where patients with high Cx26 expression are predicted to live an average of 56 months
less than those with low Cx26 expression (80 months vs. 136 months). Of note, similar to Cx30.3,
Cx26 seemed to be significantly overexpressed in tumour tissue versus healthy tissue (Figure 1).
Cx26 was significantly more upregulated in LUSC versus healthy tissue (63.5-fold), yet this was not
asssociated with a statistically significant effect on the HR (if anything, the high Cx26-expressing
cohort showed a tendency for increased survival). All other connexins analysed are represented in
Supplementary Figure S3. These observations were supported by data from The Pathology Atlas of the
Human Protein Atlas database (https://www.proteinatlas.org/pathology). This open-access database
(retrieved from TCGA) contains correlation analyses based on mRNA expression levels with respect to
clinical outcome for 17 major cancer types and almost 8000 cancer patients [59]. The database identifies
GJB2 as significantly associated with poor prognosis in lung cancer (p = 6.25 × 10−4). This remained
statistically significant in LUAD (p = 1.45 × 10−5) but not LUSC after subclassification. Of interest, of
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all the other connexin genes, this database also identified GJB3 (Cx31) to be significantly associated
with poor prognosis in lung cancer (p = 4.56 × 10−4) and in LUAD (p = 3.54 × 10−8) but not in
LUSC. This corresponds well with our own analysis (Table 2). Overall, these results clearly suggest
that connexins that are upregulated in the tumours may affect (or at least associate with) the clinical
outcome very differently in distinct tumour subtypes. Additionally, it is clear that the association
between connexin expression and prognosis was much more clear-cut in LUAD than in LUSC (Figure 3,
Table 2 and Supplementary Figure S3).
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RNA-seq analysis, this showed a tendency for poor prognosis (HR = 1.34), although this was not
deemed significant (p = 0.07). However, for the three other connexin genes we have focused on (GJB1,
GJB2 and GJB4) showed clear concordance.
2.4. Connexin Protein Expression and Subcellular Localization
Cx43 is implicated in lung cancer but substantial evidence also indicates that Cx43, in a highly
context-dependent manner, can act as both a tumour supressor and tumour promoter [16]. Our mRNA
array analysis suggested that Cx43 is weakly associated with better prognosis, especially in LUAD
(Figure 4a). However, our RNA-seq analysis did not support these findings and suggested a potential
association with poor prognosis in LUAD (Supplementary Table S1). Ultimately, analysis of the protein
expression of Cx43 is needed to provide better insight into the role of Cx43 and its correlation with
cancer. Cx43 is the most widely expressed connexin in lung epithelia, and several studies indicate
dysregulation at multiple levels: transcription (including methylation), translation (including internal
translation of truncated isoforms) and post-translational modifications (notably phosphorylation) [4].
These alterations may affect Cx43 expression levels, function and subcellular localization. In order
to gain further insight into the underlying features of Cx43 in cancer, which may explain the rather
weak association at the mRNA level, we also performed an in depth analysis of Cx43 at the protein
level. We performed an immunohistochemistry (IHC) study of Cx43 on a tissue microarray consisting
of 73 tumours (50 LUADs and 23 LUSCs). We used a validated Cx43 antibody that was absent in
paraffin-embedded cells negative for Cx43. This antibody targets the last 20 amino acids of human
Cx43, has been extensively used in other IHC studies (e.g., [48,60,61]) and was found in the Protein
Atlas (https://www.proteinatlas.org/) to show an excellent correlation between mRNA expression
and protein expression [59].
The array consisted of triplicate punch biopsies of each tumour covering the core of the tumour.
The Cx43 expression intensity varied widely (and was scored as 0: absent, 1: weak, 2: medium,
and 3: intense staining). Some tumours expressed significant levels of Cx43 with a typical pattern
in the membrane and cytoplasm (Figure 5a). Some tumours showed areas of very high expression
(Figure 5b) typically concentrated in the cytoplasm. Other tumours expressed very low or absent levels
of Cx43 (Figure 5c). Stromal cells (e.g., immune cells, muscle cells and endothelial cells) were also
frequently shown to express Cx43, as expected (Figure 5c). This is consistent with previous reports in
the lung [34,37]. Our analysis suggested that the expression levels per se did not significantly correlate
with the tumour grade or OS. This may be due to the low number of cases. However, we noted a
significant number of tumours (5 of the 23 LUSCs and 21 of the 50 LUADs) with a highly pronounced
pattern of nuclear Cx43 expression (Figure 5d). This protein could be expressed throughout most
of the tumour (Figure 5e) or in more isolated areas (quantified as positive if more than 5% of the
tumour expressed nuclear Cx43). Some tumours diplayed areas of nuclear Cx43, areas of cytoplasmic
Cx43 and areas negative for Cx43 (Figure 5f). We could not correlate the presence of nuclear Cx43
with a specific tumour subtype or stage (i.e., we detected nuclear Cx43 in both low grade and high
grade tumours, as well as in various LUAD subtypes such as acinar, papillary, micropapillary and
solid). Moreover, other stromal cells (e.g., immune cells, endothelial cells and chondrocytes) also
occasionally expressed nuclear Cx43 (Figure 5), suggesting that this nuclear translocation is driven by
microenvironmental cues.
We performed bivariate correlation analysis comparing basic tumour and patient features and
using different Cx43 staining parameters (Supplementary Table S2). Notably the expression of Cx43
(in the cytoplasm/membrane (CM) alone, or in combination with nuclear Cx43) is statistically higher
in LUSC compared to LUAD. The presence of CM Cx43 immunoreactivity also correlates with a higher
Ki67 score (suggesting Cx43 is expressed at higher levels in highly proliferating tumours). This is
not significant for nuclear Cx43 alone or in combination with CM Cx43 staining. A larger cohort and
additonal clinicopathological markers may indicate additional correlations in this aspect. Our overall
aim was to compare IHC with OS, compared to OS obtained from the in silico analysis. For this we
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used Kaplan Meier survival curves to look for associations between the Cx43 staining pattern and OS.
We identified a strong association between nuclear Cx43 and OS. Our Kaplan-Meier survival curve
analysis (Figure 6a) indicated that nuclear Cx43 was significantly associated with poor OS in NSCLC
(p = 0.014).
Figure 4. Kaplan-Meier curves of connexins known to drive lung tumorigenesis. The cohort expressing
high levels of connexin mRNA is depicted in red, and the cohort with low connexin levels is in black.
Probability refers to the likelihood of being alive at any time point. A hazard ratio (HR) below 1
suggests an association with better prognosis, whereas a HR above 1 suggests better prognosis (in the
cohort expressing high levels of connexins). (a) Cx43; (b) Cx32; (c) Cx30.3; and (d) Cx26.
We then analysed OS after stratification into LUAD and LUSC tumour subtypes. No association
was found between nuclear Cx43 and poor OS in LUSC (p = 0.578). In LUAD, however, nuclear
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Cx43 was significantly associated with poor survival (p = 0.002). There was no significant correlation
between CM Cx43 intensity and OS in NSCLC, LUSC or LUAD (based on using either moderate and
high, or mild, moderate and high, Cx43 intensity, Supplementary Figure S4a–f), although the trend
suggested Cx43 was associated with poor survival. When including patients that scored positive
for either CM Cx43 IHC or nuclear Cx43, no significance was observed in NSCLC, LUSC or LUAD
(Supplementary Figure S4g–i). However, patients classified into a single group positive for either
nuclear Cx43 staining or moderate to strong CM staining, showed significant association for poor
prognosis in NSCLC (p = 0.008) and LUAD (p = 0.005) (Supplementary Figure S4j–l). Again LUSC was
not significant, which may be due to the few patients in this cohort. This suggests Cx43 intensity may
also be a factor related to outcome.
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Figure 5. IHC of Cx43. (a) Typical example in LUSC demonstrating intense Cx43 staining with a
predominantly membranous and cytoplamsic pattern (20×). (b) Typical example in LUAD of a patchy
high Cx43 expression with a predominantly cytoplasmic expression pattern (20×). (c) Example of a
LUAD with very low or negative Cx43 expression (20×). Note that stromal cells such as endothelial
cells are still positively stained. (d) Typical example of high levels of nuclear Cx43 expression in
LUAD (20×). Note that some non-tumour cells are also sometimes positive for nuclear Cx43. (e) Low
magnification overview (4×) of a LUAD with significant areas of nuclear Cx43 expression. (f) Area of
the same tumour (10×) where nuclear Cx43 can be observed together with areas either negative for
Cx43 or with low cytoplasmic levels.
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Figure 6. Kaplan-Meier curves based on nuclear Cx43 expression detected by immunohistochemistry
of lung cancer samples. Tumours with significant nuclear Cx43 expression (over 5% of total tumours)
are depicted in red and compared with the rest of the tumour samples (in blue). p-values refer to the
log-rank test (Mantel-Cox analysis). Average survival times of the patient cohorts are listed. (a) NSCLC
(non-small cell lung cancer, refers to the merged LUAD and LUSC groups); (b) LUSC (lung squamous
cell carcinoma); (c) LUAD (lung adenocarcinoma).
3. Discussion
This study analysed connexins to identify specific changes in relation to lung cancer at the DNA
(methylation), RNA (expression) and protein (expression and subcellular localization) levels. Several
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important observations have been made. It seems clear that the mRNA expression of a number of
connexins are dramatically changed in tumours (up to 289-fold in the case of GJB6/Cx30 in LUAD).
These changes vary significantly according to tumour subtype (LUAD versus LUSC). Considering
the important role of connexins in tissue homeostasis and cancer, these observations merit further
investigation, including functional studies. It will be important to determine whether this is a mere
association or whether causation is implicated. Regardless, these changes suggest that a number of
connexins, particularly those showing a significant upregulation in tumours compared with healthy
tissue, may serve as potentially useful prognostic or diagnostic biomarkers.
Mechanistically, the regulation of the changes in connexin mRNA expression in tumour versus
healthy tissue, or indeed between tumour subtypes, remains poorly understood. We investigated
the role of connexin promoter methylation due to its well-known and important role as a regulator
of gene expression. Surprisingly, the correlation between connexin gene expression and connexin
gene methylation was poor. For instance, highly expressed connexin genes were found to be
hypermethylated while genes with low expression were hypomethylated. This is the opposite of what
would be expected. Moreover, the changes in methylation between healthy and cancer tissues did not
correlate with the corresponding changes in gene expression. For instance, significant upregulation
of a connexin did not tend to correlate with demethylation. A certain correlation could be seen
in some genes (e.g., GJB2 encoding Cx26), particularly when looking at specific probes. However,
functional studies are required to validate the significance of these observations. The direct correlation
between methylation status and transcription in cancer seems to be restricted to a subset of genes in a
tissue-specific manner, and the exact underlying mechanism remains elusive [62]. This seems to be
true for connexins as well, and further connexin gene-specific studies are required to determine any
clinical value.
Functionally, little is known regarding the role of most connexins in relation to lung cancer.
We addressed their role from an association standpoint only. However, the clear associations observed
in many cases suggest that connexins may be causally implicated in lung cancer. Indeed, this is
supported by some functional studies. Notably, results from lung cancer mouse models correlate
well with the prognostic prediction for Cx32 and Cx43 made at the mRNA level [16,26,27,29–31,63].
However, some connexins significantly upregulate their mRNA expression in lung tumours and are
associated with poor prognosis. The pathophysiological correlation of this association is unclear.
By correlating connexin mRNA expression with prognosis, we highlight connexins (e.g., Cx31) that
may need to be studied further, including at the protein level by IHC. However, it is important to keep
in mind that the correlations currently described are mere associations that do not imply causation.
Moreover, mRNA expression is typically derived from all cells present in the tumour sample (e.g., in
the lung, there would be a mix of pneumocytes, bronchial epithelium, endothelial cells, macrophages
and other cell types). Indeed, a recent study showed that cancer-associated fibroblasts can form
Cx43-mediated gap junctions with NSCLC cells to support their malignant progression [64]. The ratios
of these cell types in a tumour change. Going forward, protein expression (IHC) and specific functional
studies (in vitro and in vivo models) are critical elements that need to be addressed.
Our proof-of-principle study, looking at Cx43 protein expression in lung tumours, made a highly
surprising and important discovery: a statistically significant association between nuclear Cx43
expression and reduced OS. The very distinct and clear nuclear Cx43 expression profile, present only
in some patients, makes it an excellent putative biomarker for the disease. However, more extensive
studies are needed to verify its use in lung cancer (and potentially other cancer types). Notably, the
sample size needs to be increased, and further sub-characterization of tumour histology and other
clinicopathologic parameters needs to be correlated with Cx43 expression. It is also noteworthy that
we observed nuclear Cx43 in non-tumoural cells (e.g., endothelial cells, chondrocytes and immune
cells) in those tumours displaying nuclear Cx43. This suggests that there may be microenvironmental
conditions that regulate the nuclear translocation of Cx43. Indeed, in glioma tumours, nuclear Cx43
was observed in areas where leukocytes were present [47].
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Our IHC study also showed the importance of not relying on only the mRNA expression profile.
Indeed, the array analysis suggested (with high statistical significance) that high levels of Cx43 are
associated with better prognosis. Clearly, this does not take into consideration protein localization and
subpopulation of patients, with Cx43 protein localized to the nucleus seemingly associated with poor
prognosis. Moreover, and unlike IHC studies that specifically score the tumour cells, most studies
at the RNA level tend to average the entire tissue section, leading to significant cross-contamination
by other cells (e.g., endothelial and immune cells, known to express Cx43 and to be altered in a
tumour environment). The reliability of array probes also needs to be carefully considered. Indeed,
our Kaplan-Meier survival analysis using RNA-seq data suggested that Cx43 may be associated with
poor prognosis in LUAD (in contrast to the array analysis, but in concordance with our nuclear Cx43
association study). The reason for this discrepancy for Cx43 in LUAD is not clear. As seen here, both
approaches can give insightful information, but both will require substantial follow-up before any
clinical use.
A number of studies have described nuclear Cx43 in cell lines [50], including lung cancer
cells [51]. Nuclear Cx43 has additionally been detected in some tumours, notably in glioma [47]
and colon cancers [48], although these studies did not report an association with overall survival.
Truncated forms of Cx43 have also been detected in the nucleus of cancer cells [52]. This is particularly
interesting in light of recent reports demonstrating that the GJA1 transcript that encodes for Cx43
also independently encodes for truncated isoforms [6–8]. We showed that this also occurred in
lung cancer cells and could be regulated by modulating specific cancer signalling pathways such as
mTOR and MAPK-MNK1/2 [7]. Moreover, the major truncated Cx43 isoform, GJA1-20k, was recently
experimentally shown to translocate to the nucleus and act as a direct transcriptional activator of
N-cadherin in vivo [13]. N-cadherin is associated with EMT in cancer [65], predicts poor prognosis
in lung cancer [66] and may be a therapeutic target in chemoresistant NSCLC [67]. Indeed, our
Kaplan-Meier analysis of TCGA array data associated N-cadherin with poor prognosis in lung cancer
(data not shown). It will be of considerable interest to test whether nuclear Cx43 is correlated with
N-cadherin expression in lung tumours. Because the antibody used for IHC detects the C-terminus of
Cx43, we cannot directly determine whether the nuclear signal is due to the presence of full-length
Cx43 or any truncated form such as GJA1-20k. Further studies are needed to address this question.
Nevertheless, the link between nuclear Cx43 expression and prognosis opens up putative therapeutic
options aimed at restoring Cx43 trafficking to the membrane. This approach is particularly tantalizing
because it may serve both to disrupt the nuclear signalling cascade associated with poor prognosis and
to restore GJIC and tissue homeostasis. We have identified several FDA-approved drugs that affect
the translation of truncated Cx43 isoforms and future studies will address whether they can modify
nuclear Cx43 localization or the tumour phenotype.
4. Materials and Methods
4.1. Immunohistochemistry
IHC was performed using the avidin-biotin-peroxidase technique. Five-micron-thick sections
were cut from formalin-fixed, paraffin-embedded cell pellets and mounted on poly-L-lysine-coated
glass slides. Sections were deparaffinized in xylene and rehydrated in graded alcohol. Endogenous
peroxidase was blocked by immersing the sections in 0.1% hydrogen peroxidase in absolute methanol
for 20 min. For antigen retrieval, the tissue sections were heated in a pressure cooker in 10 mM citric
acid monohydrate, pH 6.0, for 5 min and then incubated with primary antibodies for 60 min at room
temperature. IHC was performed with the Benchmark XT slide stainer (Ventana Medical Systems, Inc.,
Tucson, AZ, USA). The primary antibody used was anti-Cx43 (C6219, Sigma-Aldrich Quimica SL,
Madrid, Spain) at 1:1000 dilution. All slides were haematoxylin-counterstained, dehydrated and
mounted. Negative controls were performed by omitting the primary antibody and showed minimal
non-specific signal. The immunostaining intensity was scored as follows: negative, 0; weak, 1;
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moderate, 2; and intense, 3. Nuclear Cx43 expression was considered to be significant when more than
5% of the tumour samples showed nuclear staining.
4.2. Statistics
Statistical studies were performed with the Statistical Package for the Social Sciences (SPSS 25.0;
SPSS Inc., Chicago, IL, USA). Statistical significance for the Kaplan-Meier curves were considered at
p < 0.05 using log-rank (Mantel-Cox) analysis. Bivariate correlations were analysed using two-tailed
Pearson’s correlation coefficient with significance set at p < 0.05.
4.3. Human Tissue Specimens and Tissue Microarray
Tissue microarrays containing 73 cases of primary lung cancer were obtained from the pathology
department. Triplicates of each tumour were used in the tissue microarray. All of the tissue specimens
for this study were obtained with informed patient consent from the Hospital Vall d’Hebron Biobank,
and the use of these specimens for this study was approved by the ethics committee of Hospital Vall
d’Hebron (PR(AG)327/2014).
4.4. Bioinformatic Analysis
Gene expression analysis: Connexin mRNA expression in lung tumours and in corresponding
normal tissues was analysed by using data from The Cancer Genome Atlas (TCGA) using FireBrowseR
(http://firebrowse.org/) following the standard input and output values defined by the software [53].
Our observations were verified using the TCGA Wanderer tool (http://maplab.imppc.org/wanderer/)
based on Illumina HiSeq RNA-seq analysis [54].
Kaplan-Meier survival curves (mRNA expression): Overall survival (OS) was derived both from
TCGA array data of lung cancer and from pan-cancer RNA-seq data. All analyses were performed
online (http://kmplot.com/) using the standard setting as defined by the software [58], with the
following exception: Patients were split using “Auto select best cutoff”. Survival refers to OS. The cutoff
for significance was set to a strict p < 0.001. Additional verifications and analyses were performed using
the Pathology Atlas of the Human Protein Atlas database (https://www.proteinatlas.org/pathology)
using a standard setting and a strict cutoff value for significance set to p < 0.001. This open-access
database (retrieved from The Cancer Genome Atlas [TCGA]) contains correlation analyses based
on mRNA expression levels with respect to clinical outcome for 17 major cancer types and almost
8000 cancer patients [59].
Methylation analysis: We used an online (http://ualcan.path.uab.edu/) analysis tool [55] to
gain insight into the correlation between changes in connexin mRNA expression in lung tumours
and changes in gene methylation. Standard pre-determined settings were used. We used the
TCGA Wanderer tool (http://maplab.imppc.org/wanderer/) [54] to analyse the methylation status of
individual probes and the correlation to gene expression in the tumours.
5. Conclusions
In conclusion we have found that major changes in some specific connexin mRNAs often occur in
lung tumours but in general this do not correlate well in relation to changes in promoter methylation.
Connexin mRNA expression can however correlate with both good and poor prognosis, which depends
on the connexin isoform analysed and the histological subtype (LUAD versus LUSC). In addition to
changes in mRNA expression, it is clear that protein location and functionality is critical. In this study,
we identified a subset of tumours that exhibited a unique strong nuclear Cx43 expression pattern
that predicted worse overall survival. The prognostic value was highly significant in LUAD, and
larger cohorts will be needed to definitively assess the correlation in LUSC. This study highlights
the importance of analysis of connexin expression at the protein level, particularly the subcellular
localization. It also proposes that modulation of Cx43 trafficking may be a useful therapeutic strategy.
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